Year: 2023
Type: conference-abstract
Abstract: Introduction Immune surveillance, distribution, interactions, and antigen presentation within the tumor microenvironment (TME) may influence anti-tumor reactivity and survival. Methods Dichotomized newly diagnosed treatment-naïve IDH1 wild-type glioblastoma, negative MGMT promotor methylation (65%), short-term (STS; ≤ 6 months; mean age 66 years; n=10) or long-term (LTS; >2 years; mean age 50 years; n=10) survivors, were profiled using high dimensional fluorescence multiplex staining spatial analysis of the TME using a panel of 26 markers. Results The amounts of specific immune cells (CD4+, CD8+, FOXP3+, CD11c+, CD20+, CD68+, CD205+, NKG2D+) were similar between cohorts, except STS were enriched with CD163+ expressing macrophages and LTS had more P2RY12+ microglia throughout the TME. There was minimal MHC-I expression and no difference in MHC-II on the myeloid populations (CD68+, CD11c+, CD163+, P2RY12+, and/or in combination) in both cohorts. TIM-3 was the only immune regulator substantially expressed on P2RY12+ microglia and the other myeloid populations, irrespective of survival. Perivascular clustering of CD11c+CD163+ cells was enriched in STS cases. The TME in LTS cases demonstrated adaptive immune activation processes, including CD11c+P2RY12+CD205+ microglia interacting with CD45RO− naïve, non-exhausted (PD-1−, LAG3−, Tim3−) CD8+ T cells expressing the LCK+ immune synaptic marker. Conclusion Immune activation interactions between CD8+ T cells and microglia in the TME may help determine STS versus LTS in GBM patients.
Source: The Journal of Immunology
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4385687706